Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness of Treating Post-COVID-19 Conditions (Long COVID) With the SARS-CoV-2 Specific Monoclonal Antibody, Sipavibart

NCT07021794 is registered in ClinicalTrials.gov with Nancy Klimas as lead sponsor.

NCT NCT07021794
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07021794 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness of Treating Post-COVID-19 Conditions (Long COVID) With the SARS-CoV-2 Specific Monoclonal Antibody, Sipavibart
Lead sponsor
Nancy Klimas
Phase
Phase 2
Overall status
Recruiting
Start date
July 28, 2025
Completion date
September 30, 2027
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

post-covid / long-covid